{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}],"title":"Complete Response & Stringent Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"title":"Very Good Partial Response (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}],"title":"Minimal Response (MR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"19"}]}],"title":"Overall Response >/= PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Response rate in older adults with mildly symptomatic multiple myeloma to single agent lenalidomide, lenalidomide prednisone and lenalidomide low dose dexamethasone in patients with suboptimal responses to lenalidomide monotherapy. The study used the uniform response assessment of the International Myeloma Working Group with the addition of MR (minimal response) (Durie et al, 2006; Kumar et al, 2016). MR was defined as a 25-49% decrease in serum M spike, and a 50-89% improvement in urine M spike. For patients without a measurable serum or urine M spike, a 25-49% decrease in the difference between the involved and uninvolved free light chains was required. The response in this trial is defined as complete remission (CR), stringent complete remission (SRC), very good partial remission (VGPR) and partial remission (PR) and minimal response (MR).","groups":[{"description":"Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.","id":"OG000","title":"Response Adapted Therapy"},{"description":"Participants treated with single agent lenalidomide","id":"OG001","title":"Single Agent Lenalidomide"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 participant could not be evaluated for response.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks up to 12 months","title":"Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}